LUME-Ovar 1: Nintedanib (BIBF 1120) or Placebo in Combination With Paclitaxel and Carboplatin in First Line Treatment of Ovarian Cancer
Completed
The trial will be performed to evaluate if BIBF 1120 in combination with paclitaxel and carboplatin is more effective than placebo in combination with paclitaxel and carboplatin in first-line treatment of patients with advanced ovarian cancer. Safety information about BIBF1120/paclitaxel/carboplatin will be obtained.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
11/03/2017
Locations: 1199.15.10113 Boehringer Ingelheim Investigational Site, Tucson, Arizona +280 locations
Conditions: Ovarian Neoplasms, Peritoneal Neoplasms
Phase 1b/2 Study of Carfilzomib, Carboplatin, and Etoposide in Patients With Previously Untreated Extensive Stage Small-cell Lung Cancer
Completed
The purpose of this study is to determine the maximum tolerated dose and assess the safety, tolerability and activity of carfilzomib given in combination with carboplatin and etoposide as initial therapy for patients with extensive-stage small-cell lung cancer (ES SCLC).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/26/2017
Locations: Yale University, Yale Cancer Center, New Haven, Connecticut +16 locations
Conditions: Extensive-Stage Small-Cell Lung Cancer
Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney Tumors
Completed
This phase II trial is studying how well combination chemotherapy, radiation therapy, and/or surgery work in treating patients with high-risk kidney tumors. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving combination chemotherapy together with radiat... Read More
Gender:
ALL
Ages:
29 years and below
Trial Updated:
06/22/2017
Locations: Children's Hospital of Alabama, Birmingham, Alabama +186 locations
Conditions: Childhood Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma, Clear Cell Sarcoma of the Kidney, Papillary Renal Cell Carcinoma, Rhabdoid Tumor of the Kidney, Stage I Renal Cell Cancer, Stage I Renal Wilms Tumor, Stage II Renal Cell Cancer, Stage II Renal Wilms Tumor, Stage III Renal Cell Cancer, Stage III Renal Wilms Tumor, Stage IV Renal Cell Cancer, Stage IV Renal Wilms Tumor
Safety and Efficacy of Carboplatin/Paclitaxel and Carboplatin/Paclitaxel/Bevacizumab With and Without Pictilisib in Previously Untreated Advanced or Recurrent Non-small Cell Lung Cancer
Completed
This multicenter, randomized, double-blind, placebo-controlled trial will evaluate the efficacy and safety of carboplatin/paclitaxel and carboplatin/paclitaxel/bevacizumab with and without pictilisib in particpants with previously untreated advanced or recurrent non-small cell lung cancer (NSCLC). Particpants will be randomized to receive 4 cycles of carboplatin (C)/paclitaxel (P) and either pictilisib or placebo, with (participants with non-squamous NSCLC) or without (participants with squamous... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/21/2017
Locations: Alabama Oncology, Birmingham, Alabama +119 locations
Conditions: Non-Small Cell Lung Cancer
Surgery in Treating Children With Neuroblastoma
Completed
RATIONALE: Surgery alone may be effective in treating children with neuroblastoma. PURPOSE: Phase III trial to study the effectiveness of surgery alone in treating children who have neuroblastoma.
Gender:
ALL
Ages:
21 years and below
Trial Updated:
03/09/2017
Locations: University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, Alabama +234 locations
Conditions: Neuroblastoma
TRINOVA-3: A Study of AMG 386 or AMG 386 Placebo in Combination With Paclitaxel and Carboplatin to Treat Ovarian Cancer
Terminated
The purpose of this study is to determine whether AMG 386 or AMG 386 Placebo in combination with Paclitaxel and Carboplatin are effective in the treatment of ovarian cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
02/22/2017
Locations: Research Site, Birmingham, Alabama +309 locations
Conditions: Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cancer
A Study Evaluating RO5479599 in Combination With Carboplatin and Paclitaxel in Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC) of Squamous Histology
Terminated
A multi-center Phase Ib/II study of the combination of RO5479599 with carboplatin and paclitaxel once in every 3 week (q3w) regimen to evaluate the safety and tolerability.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/24/2017
Locations: Not set, Toronto, Ontario +5 locations
Conditions: Squamous Non-Small Cell Lung Cancer
Gefitinib With or Without Carboplatin and Paclitaxel in Treating Older Patients With Unresectable or Metastatic Non-Small Cell Lung Cancer
Completed
RATIONALE: Biological therapies such as gefitinib may interfere with the growth of cancer cells and slow the growth of the tumor. Drugs used in chemotherapy such as carboplatin and paclitaxel use different ways to stop tumor cells from dividing so they stop growing or die. Combining gefitinib with carboplatin and paclitaxel may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving gefitinib alone or together with carboplatin and paclitaxel works in treating older patie... Read More
Gender:
ALL
Ages:
Between 65 years and 120 years
Trial Updated:
12/12/2016
Locations: Mayo Clinic Scottsdale, Scottsdale, Arizona +140 locations
Conditions: Lung Cancer
Combination Chemotherapy With or Without Filgrastim in Treating Patients With Previously Untreated Extensive-Stage Small Cell Lung Cancer
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Colony-stimulating factors such as filgrastim may increase the number of immune cells found in bone marrow or peripheral blood and may help a person's immune system recover from the side effects of chemotherapy. PURPOSE: Phase II trial to compare the effectiveness of combination chemotherapy with or without filgrastim in treating patients who have extensive-stage small cell lu... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/05/2016
Locations: CCOP - Scottsdale Oncology Program, Scottsdale, Arizona +23 locations
Conditions: Lung Cancer
Combination Chemotherapy and Exisulind in Treating Patients With Extensive-Stage Small Cell Lung Cancer
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Exisulind may make tumor cells more sensitive to chemotherapy. Combining chemotherapy with exisulind may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining chemotherapy with exisulind in treating patients who have extensive-stage small cell lung cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/05/2016
Locations: Northeast Alabama Regional Medical Center, Anniston, Alabama +82 locations
Conditions: Lung Cancer
A Phase 2 Study Comparing Chemotherapy in Combination With OGX-427 or Placebo in Patients With Bladder Cancer
Completed
The primary objective of this study is to ascertain whether there is evidence of longer survival relative to the control arm for three comparisons: 600 mg OGX-427 Arm to control Arm; 1000 mg OGX-427 Arm to control Arm; and pooled 600 mg and 1000 mg OGX-427 Arms to control Arm.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/06/2016
Locations: City of Hope National Medical Center, Duarte, California +54 locations
Conditions: Urologic Neoplasms, Metastatic Bladder Cancer, Urinary Tract Neoplasms
Combination Chemotherapy With or Without Trastuzumab in Treating Women With Breast Cancer
Completed
Primary objective: * Compare disease-free survival in women with human epidermal growth factor receptor 2 (HER2)-neu-expressing node-positive or high-risk node-negative operable breast cancer treated with adjuvant doxorubicin, cyclophosphamide, and docetaxel with or without trastuzumab (Herceptin) vs trastuzumab, docetaxel, and carboplatin. Secondary objective: * Compare overall survival of participants treated with these regimens. * Compare the toxic effects (including cardiac) of these regi... Read More
Gender:
FEMALE
Ages:
Between 18 years and 70 years
Trial Updated:
09/26/2016
Locations: Sanofi-Aventis Administrative Office, Bridgewater, New Jersey +41 locations
Conditions: Breast Neoplasms